Vitamin B 12
(FDJOLVPMNUYSCM-WZHZPDAFSA-L)
Structure
- SMILES
- OC[C@H]1O[C@@H]([C@@H]([C@@H]1OP(=O)(O[C@@H](CNC(=O)CC[C@@]1(C)C2=N[C@H]([C@@H]1CC(=O)N)[C@]1(C)[N-]/C(=C(/C)\C3=N/C(=C\C4=N/C(=C\2/C)/[C@@H](CCC(=O)N)C4(C)C)/[C@H]([C@]3(C)CC(=O)N)CCC(=O)N)/[C@H]([C@]1(C)CC(=O)N)CCC(=O)N)C)[O-])O)n1cnc2c1cc(C)c(c2)C.[C-]#N.[Co+3]
- Type(s)
- Approved; Nutraceutical
- ATC code(s)
- B03AE01; B03BA01; B03BA51
- Molecular Formula:
- C63H88CoN14O14P
- Molecular Weight:
- 1355.370
- Log P:
- 6.7119
- Hydrogen Bond Acceptor:
- 27
- Hydrogen Bond Donor:
- 9
- TPSA:
- 484.42
- CAS Number(s):
- 68-19-9
Synonym(s)
1.
Vitamin B 12
2.
Cobalamin
3.
Cyanocobalamin
4.
Cobalamins
5.
Eritron
6.
Vitamin B12
7.
B 12, Vitamin
8.
B12, Vitamin
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Expired product administered | FAERS: 13 | US FAERS | |
| 2 | Fatigue | FAERS: 13 Canada Vigilance: 4 | Canada Vigilance OFFSIDES US FAERS | |
| 3 | Pruritus | FAERS: 12 Canada Vigilance: 3 | Canada Vigilance SIDER US FAERS | |
| 4 | Injection site pain | FAERS: 9 | US FAERS | |
| 5 | No adverse event | FAERS: 9 | US FAERS | |
| 6 | Tremor | FAERS: 9 | US FAERS | |
| 7 | Urticaria | FAERS: 8 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 8 | Dizziness | FAERS: 7 Canada Vigilance: 1 | Canada Vigilance OFFSIDES SIDER US FAERS | |
| 9 | Drug ineffective | FAERS: 7 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 10 | Myalgia | FAERS: 6 | SIDER US FAERS | |
| 11 | Arthralgia | FAERS: 5 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 12 | Chromaturia | FAERS: 5 | US FAERS | |
| 13 | Headache | FAERS: 5 Canada Vigilance: 2 | Canada Vigilance SIDER US FAERS | |
| 14 | Hypersensitivity | FAERS: 5 Canada Vigilance: 6 | Canada Vigilance US FAERS | |
| 15 | Product quality issue | FAERS: 5 | US FAERS | |
| 16 | Feeling abnormal | FAERS: 4 | OFFSIDES US FAERS | |
| 17 | Flushing | FAERS: 4 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 18 | Nausea | FAERS: 4 Canada Vigilance: 2 | Canada Vigilance SIDER US FAERS | |
| 19 | Pain | FAERS: 4 Canada Vigilance: 5 | Canada Vigilance OFFSIDES SIDER US FAERS | |
| 20 | Product storage error | FAERS: 4 | US FAERS | |
| 21 | Cerebral atrophy | FAERS: 3 | US FAERS | |
| 22 | Injection site erythema | FAERS: 3 | US FAERS | |
| 23 | Lethargy | FAERS: 3 | US FAERS | |
| 24 | Malaise | FAERS: 3 | US FAERS | |
| 25 | Myoclonus | FAERS: 3 | US FAERS | |
| 26 | Abscess | FAERS: 2 | US FAERS | |
| 27 | Accidental exposure to product | FAERS: 2 | US FAERS | |
| 28 | Agitation | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 29 | Angioedema | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 30 | Arthritis | FAERS: 2 | OFFSIDES SIDER US FAERS | |
| 31 | Asthenia | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance OFFSIDES SIDER US FAERS | |
| 32 | Chest discomfort | FAERS: 2 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 33 | Chorea | FAERS: 2 | US FAERS | |
| 34 | Dermatitis acneiform | FAERS: 2 | US FAERS | |
| 35 | Endocarditis | FAERS: 2 | US FAERS | |
| 36 | Feeling jittery | FAERS: 2 | US FAERS | |
| 37 | Injection site warmth | FAERS: 2 | US FAERS | |
| 38 | Intentional product misuse | FAERS: 2 | US FAERS | |
| 39 | Intentional product use issue | FAERS: 2 | US FAERS | |
| 40 | Menorrhagia | FAERS: 2 | US FAERS | |
| 41 | Musculoskeletal Pain | FAERS: 2 | OFFSIDES US FAERS | |
| 42 | Oropharyngeal pain | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 43 | Pallor | FAERS: 2 | US FAERS | |
| 44 | Palpitations | FAERS: 2 | US FAERS | |
| 45 | Reaction to preservatives | FAERS: 2 | US FAERS | |
| 46 | Tinnitus | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance OFFSIDES US FAERS | |
| 47 | Unevaluable event | FAERS: 2 | US FAERS | |
| 48 | Vomiting | FAERS: 2 | SIDER US FAERS | |
| 49 | Abdominal Pain | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance OFFSIDES US FAERS | |
| 50 | Anaphylactic shock | FAERS: 1 | SIDER US FAERS | |
| 51 | Anxiety | FAERS: 1 | OFFSIDES SIDER US FAERS | |
| 52 | Burning sensation | FAERS: 1 | US FAERS | |
| 53 | Cellulitis | FAERS: 1 | OFFSIDES US FAERS | |
| 54 | Chronic Fatigue Syndrome | FAERS: 1 | US FAERS | |
| 55 | Conjunctivitis | FAERS: 1 | US FAERS | |
| 56 | Constipation | FAERS: 1 | US FAERS | |
| 57 | Deafness | FAERS: 1 | US FAERS | |
| 58 | Deformity | FAERS: 1 | US FAERS | |
| 59 | Dermatitis | FAERS: 1 | SIDER US FAERS | |
| 60 | Drug administration error | FAERS: 1 | US FAERS | |
| 61 | Drug dispensing error | FAERS: 1 | US FAERS | |
| 62 | Drug dose omission | FAERS: 1 | OFFSIDES US FAERS | |
| 63 | Drug effect incomplete | FAERS: 1 | US FAERS | |
| 64 | Drug level increased | FAERS: 1 | US FAERS | |
| 65 | Dysarthria | FAERS: 1 | US FAERS | |
| 66 | Dysgeusia | FAERS: 1 | US FAERS | |
| 67 | Dysmyelination | FAERS: 1 | US FAERS | |
| 68 | Dyspepsia | FAERS: 1 | SIDER US FAERS | |
| 69 | Eczema | FAERS: 1 | US FAERS | |
| 70 | Eosinophilic pustular folliculitis | FAERS: 1 | US FAERS | |
| 71 | Erythema | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 72 | Expired drug administered | FAERS: 1 | US FAERS | |
| 73 | Extraskeletal Myxoid Chondrosarcoma | FAERS: 1 | US FAERS | |
| 74 | Facial Pain | FAERS: 1 | US FAERS | |
| 75 | Gastrointestinal Pain | FAERS: 1 | US FAERS | |
| 76 | Hypersomnia | FAERS: 1 | US FAERS | |
| 77 | Impaired work ability | FAERS: 1 | US FAERS | |
| 78 | Inappropriate schedule of drug administration | FAERS: 1 | US FAERS | |
| 79 | Incorrect drug administration duration | FAERS: 1 | US FAERS | |
| 80 | Incorrect product administration duration | FAERS: 1 | US FAERS | |
| 81 | Infection | FAERS: 1 | SIDER US FAERS | |
| 82 | Injection related reaction | FAERS: 1 | US FAERS | |
| 83 | Injection site abscess | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 84 | Injection site hypersensitivity | FAERS: 1 | US FAERS | |
| 85 | Injection site infection | FAERS: 1 | US FAERS | |
| 86 | Injection site mass | FAERS: 1 | US FAERS | |
| 87 | Injection site pruritus | FAERS: 1 | US FAERS | |
| 88 | Injection site urticaria | FAERS: 1 | US FAERS | |
| 89 | Injection site vesicles | FAERS: 1 | US FAERS | |
| 90 | Joint swelling | FAERS: 1 | US FAERS | |
| 91 | Latex allergy | FAERS: 1 | US FAERS | |
| 92 | Lymphadenopathy | FAERS: 1 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 93 | Lymphoma | FAERS: 1 | US FAERS | |
| 94 | Memory impairment | FAERS: 1 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 95 | Muscle contusion | FAERS: 1 | US FAERS | |
| 96 | Muscle tightness | FAERS: 1 | US FAERS | |
| 97 | Myocardial Infarction | FAERS: 1 | US FAERS | |
| 98 | Nasopharyngitis | FAERS: 1 | US FAERS | |
| 99 | Necrosis | FAERS: 1 | US FAERS | |
| 100 | Night sweats | FAERS: 1 | US FAERS | |
| 101 | Nodule | FAERS: 1 | OFFSIDES US FAERS | |
| 102 | Oropharyngeal swelling | FAERS: 1 | US FAERS | |
| 103 | Papule | FAERS: 1 | US FAERS | |
| 104 | Paranoia | FAERS: 1 | US FAERS | |
| 105 | Product contamination | FAERS: 1 | US FAERS | |
| 106 | Product dose omission | FAERS: 1 | US FAERS | |
| 107 | Product expiration date issue | FAERS: 1 | US FAERS | |
| 108 | Product formulation issue | FAERS: 1 | US FAERS | |
| 109 | Product use issue | FAERS: 1 | US FAERS | |
| 110 | Propionibacterium infection | FAERS: 1 | US FAERS | |
| 111 | Reaction to excipient | FAERS: 1 | US FAERS | |
| 112 | Renal pain | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 113 | Respiratory Depression | FAERS: 1 | US FAERS | |
| 114 | Restlessness | FAERS: 1 | US FAERS | |
| 115 | Rubber sensitivity | FAERS: 1 | US FAERS | |
| 116 | Secretion discharge | FAERS: 1 | US FAERS | |
| 117 | Septic Shock | FAERS: 1 | OFFSIDES US FAERS | |
| 118 | Sinus headache | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 119 | Skin Wrinkling | FAERS: 1 | US FAERS | |
| 120 | Soft Tissue Infection | FAERS: 1 | US FAERS | |
| 121 | Somnolence | FAERS: 1 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 122 | Status Epilepticus | FAERS: 1 | US FAERS | |
| 123 | Swelling | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance SIDER US FAERS | |
| 124 | Syncope | FAERS: 1 | US FAERS | |
| 125 | Tachycardia | FAERS: 1 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 126 | Tension | FAERS: 1 | SIDER US FAERS | |
| 127 | Therapeutic response unexpected with drug substitution | FAERS: 1 | US FAERS | |
| 128 | Throat irritation | FAERS: 1 | US FAERS | |
| 129 | Tonsillitis | FAERS: 1 | US FAERS | |
| 130 | Toxicity to various agents | FAERS: 1 | US FAERS | |
| 131 | Ulcer | FAERS: 1 | US FAERS | |
| 132 | Urine output increased | FAERS: 1 | US FAERS | |
| 133 | Venous Injury | FAERS: 1 | US FAERS | |
| 134 | Visual Impairment | FAERS: 1 | US FAERS | |
| 135 | Vitreous degeneration | FAERS: 1 | US FAERS | |
| 136 | Wheezing | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 137 | Wound infection bacterial | FAERS: 1 | US FAERS | |
| 138 | Wrong drug administered | FAERS: 1 | US FAERS | |
| 139 | furuncle | FAERS: 1 | OFFSIDES US FAERS | |
| 140 | Abasia | OFFSIDES | ||
| 141 | Abdominal adhesions | OFFSIDES | ||
| 142 | Abdominal mass | OFFSIDES | ||
| 143 | Abnormal vision | OFFSIDES | ||
| 144 | Accidental overdose | Canada Vigilance: 1 | Canada Vigilance | |
| 145 | Acidosis | OFFSIDES | ||
| 146 | Actinomycosis | OFFSIDES | ||
| 147 | Adenocarcinoma | OFFSIDES | ||
| 148 | Agoraphobia | OFFSIDES | ||
| 149 | Albumin globulin ratio decreased | OFFSIDES | ||
| 150 | Alveolitis | OFFSIDES | ||
| 151 | Amnesia | OFFSIDES | ||
| 152 | Anhedonia | OFFSIDES | ||
| 153 | Anorexia | OFFSIDES | ||
| 154 | Anticonvulsant drug level decreased | OFFSIDES | ||
| 155 | Aphonia | OFFSIDES | ||
| 156 | Aphthous Stomatitis | OFFSIDES | ||
| 157 | Arteriosclerosis | OFFSIDES | ||
| 158 | Arthroscopy | OFFSIDES | ||
| 159 | Aspiration Pneumonia | OFFSIDES | ||
| 160 | Asthma | OFFSIDES | ||
| 161 | Ataxia | OFFSIDES | ||
| 162 | Atrioventricular Block | OFFSIDES | ||
| 163 | Back Pain | SIDER | ||
| 164 | Bereavement | OFFSIDES | ||
| 165 | Bifascicular block | OFFSIDES | ||
| 166 | Bipolar Disorder | OFFSIDES | ||
| 167 | Blood 1,25-dihydroxycholecalciferol decreased | OFFSIDES | ||
| 168 | Blood Glucose | OFFSIDES | ||
| 169 | Blood bilirubin unconjugated increased | OFFSIDES | ||
| 170 | Blood chloride increased | OFFSIDES | ||
| 171 | Blood creatinine increased | OFFSIDES | ||
| 172 | Blood glucose decreased | OFFSIDES | ||
| 173 | Blood parathyroid hormone increased | OFFSIDES | ||
| 174 | Blood phosphorus increased | OFFSIDES | ||
| 175 | Blood pressure fluctuation | OFFSIDES | ||
| 176 | Blood sodium abnormal | OFFSIDES | ||
| 177 | Blood sodium | OFFSIDES | ||
| 178 | Blood thyroid stimulating hormone | OFFSIDES | ||
| 179 | Blood urea increased | OFFSIDES | ||
| 180 | Blood urine present | OFFSIDES | ||
| 181 | Bone pain | OFFSIDES | ||
| 182 | Bronchial Obstruction | OFFSIDES | ||
| 183 | Bronchial secretion retention | OFFSIDES | ||
| 184 | Bronchitis | OFFSIDES | ||
| 185 | Bronchospasm | Canada Vigilance: 1 | Canada Vigilance | |
| 186 | Bruxism | OFFSIDES | ||
| 187 | Bursitis | OFFSIDES | ||
| 188 | Carotid artery occlusion | OFFSIDES | ||
| 189 | Cataract operation | OFFSIDES | ||
| 190 | Cataract | OFFSIDES | ||
| 191 | Cholangiolitis | OFFSIDES | ||
| 192 | Cholecystitis | OFFSIDES | ||
| 193 | Chronic active hepatitis | OFFSIDES | ||
| 194 | Claustrophobia | OFFSIDES | ||
| 195 | Deafness Neurosensory | OFFSIDES | ||
| 196 | Debridement | OFFSIDES | ||
| 197 | Dehydration | OFFSIDES | ||
| 198 | Demyelination | OFFSIDES | ||
| 199 | Dental Fistula | OFFSIDES | ||
| 200 | Device interaction | OFFSIDES | ||
| 201 | Diabetes | OFFSIDES | ||
| 202 | Drug diversion | OFFSIDES | ||
| 203 | Duodenal Ulcer | OFFSIDES | ||
| 204 | Economic problem | OFFSIDES | ||
| 205 | Emotional distress | OFFSIDES | ||
| 206 | Eosinophil percentage increased | OFFSIDES | ||
| 207 | Epistaxis | OFFSIDES | ||
| 208 | Erectile dysfunction | OFFSIDES | ||
| 209 | Eschar | OFFSIDES | ||
| 210 | Excoriation | OFFSIDES | ||
| 211 | Fat necrosis | OFFSIDES | ||
| 212 | Febrile Neutropenia | OFFSIDES | ||
| 213 | Fibromyalgia | OFFSIDES | ||
| 214 | Fluid overload | OFFSIDES | ||
| 215 | Full blood count decreased | OFFSIDES | ||
| 216 | Gambling | OFFSIDES | ||
| 217 | Gastric Bypass | OFFSIDES | ||
| 218 | General physical health deterioration | OFFSIDES | ||
| 219 | General symptom | Canada Vigilance: 1 | Canada Vigilance | |
| 220 | Globulinuria | OFFSIDES | ||
| 221 | Glossitis | SIDER | ||
| 222 | Granulomatous liver disease | OFFSIDES | ||
| 223 | Hemiparesis | OFFSIDES | ||
| 224 | Hyperkeratosis | OFFSIDES | ||
| 225 | Hypoaesthesia facial | OFFSIDES | ||
| 226 | Hypomania | OFFSIDES | ||
| 227 | Hyporeflexia | OFFSIDES | ||
| 228 | Incoherent | OFFSIDES | ||
| 229 | Incontinence | OFFSIDES | ||
| 230 | Increased upper airway secretion | OFFSIDES | ||
| 231 | Infusion site mobility decreased | OFFSIDES | ||
| 232 | Injection Site Reaction | Canada Vigilance: 2 | Canada Vigilance | |
| 233 | Injection site inflammation | Canada Vigilance: 1 | Canada Vigilance | |
| 234 | Intervertebral Disc Degeneration | OFFSIDES | ||
| 235 | Joint injury | OFFSIDES | ||
| 236 | Kidney Failure | OFFSIDES | ||
| 237 | Leukodystrophy | OFFSIDES | ||
| 238 | Leukopenia neonatal | OFFSIDES | ||
| 239 | Leukopenia | Canada Vigilance: 1 | Canada Vigilance | |
| 240 | Lung Injury | OFFSIDES | ||
| 241 | Lymph node palpable | OFFSIDES | ||
| 242 | Lymphedema | OFFSIDES | ||
| 243 | Lymphocyte count decreased | OFFSIDES | ||
| 244 | Lymphocyte stimulation test positive | OFFSIDES | ||
| 245 | Malignant neoplasm progression | OFFSIDES | ||
| 246 | Mastication disorder | OFFSIDES | ||
| 247 | Maxillofacial operation | OFFSIDES | ||
| 248 | Mediastinitis | OFFSIDES | ||
| 249 | Mental impairment | OFFSIDES | ||
| 250 | Mental status changes | OFFSIDES | ||
| 251 | Metabolic acidosis | OFFSIDES | ||
| 252 | Multiple Sclerosis | OFFSIDES | ||
| 253 | Multiple sclerosis relapse | OFFSIDES | ||
| 254 | Muscle Weakness | OFFSIDES | ||
| 255 | Musculoskeletal chest pain | OFFSIDES | ||
| 256 | Musculoskeletal discomfort | SIDER | ||
| 257 | Myelitis | OFFSIDES | ||
| 258 | Myringitis | OFFSIDES | ||
| 259 | Nephrolithiasis | OFFSIDES | ||
| 260 | Nervousness | SIDER | ||
| 261 | Neurodermatitis | OFFSIDES | ||
| 262 | Neuromyelitis Optica | OFFSIDES | ||
| 263 | Neutrophil count decreased | OFFSIDES | ||
| 264 | Nonspecific reaction | OFFSIDES | ||
| 265 | Ocular icterus | OFFSIDES | ||
| 266 | Osteoporosis | OFFSIDES | ||
| 267 | Overdose | OFFSIDES | ||
| 268 | Pachymeningitis | OFFSIDES | ||
| 269 | Pancreatic Cyst | OFFSIDES | ||
| 270 | Peripheral swelling | Canada Vigilance: 1 | Canada Vigilance | |
| 271 | Perirectal abscess | OFFSIDES | ||
| 272 | Perivascular dermatitis | OFFSIDES | ||
| 273 | Pharyngeal swelling | Canada Vigilance: 1 | Canada Vigilance | |
| 274 | Pneumoconiosis | OFFSIDES | ||
| 275 | Polymenorrhea | OFFSIDES | ||
| 276 | Presyncope | Canada Vigilance: 1 | Canada Vigilance | |
| 277 | Prothrombin level decreased | OFFSIDES | ||
| 278 | Psychomotor skills impaired | OFFSIDES | ||
| 279 | Renal cyst | OFFSIDES | ||
| 280 | Respiratory tract congestion | OFFSIDES | ||
| 281 | Rhinitis | SIDER | ||
| 282 | Sarcoidosis | OFFSIDES | ||
| 283 | Sinusitis | OFFSIDES | ||
| 284 | Skin Erosion | OFFSIDES | ||
| 285 | Skin lesion | OFFSIDES | ||
| 286 | Stress | OFFSIDES | ||
| 287 | Sudden death | OFFSIDES | ||
| 288 | Therapeutic procedure | OFFSIDES | ||
| 289 | Therapeutic product effect decreased | Canada Vigilance: 1 | Canada Vigilance | |
| 290 | Thoracic vertebral fracture | OFFSIDES | ||
| 291 | Thrombosis | SIDER | ||
| 292 | Tooth Extraction | OFFSIDES | ||
| 293 | Ureteral stent insertion | OFFSIDES | ||
| 294 | Vertigo | Canada Vigilance: 1 | Canada Vigilance | |
| 295 | Violence-related symptom | OFFSIDES | ||
| 296 | Vitreous Detachment | OFFSIDES | ||
| 297 | Weight Gain | OFFSIDES | ||
| 298 | Wrong technique in drug usage process | OFFSIDES | ||
| 299 | effusion | OFFSIDES |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.